Zeper, Lara W. http://orcid.org/0000-0002-6429-6280
Smith, Edward R.
ter Braake, Anique D.
Tinnemans, Paul T.
de Baaij, Jeroen H. F. http://orcid.org/0000-0003-2372-8486
Hoenderop, Joost G. J. http://orcid.org/0000-0002-1816-8544
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (016.186.012, 016.130.668)
Nierstichting (14OKG17, 16TKI02, 21OK022)
Sylvia and Charles Viertel Charitable Foundation (PG-004-2018)
Health~Holland (LSHM17034-SGF)
Article History
Received: 20 April 2022
Accepted: 20 October 2022
First Online: 3 November 2022
Declarations
:
: ERS is a stockholder of Calciscon AG (Biel, Switzerland), which commercializes the T50 test and also reports research funding from Sanofi, unrelated to the current study.
: All participants gave written informed consent, and the study was approved by local ethics committee (Melbourne Health Research and Ethics Committee ref.: 2012.141) and was conducted in accordance with the Declaration of Helsinki.